Literature DB >> 23253399

A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases.

A A P Slesser1, C Simillis, R Goldin, G Brown, S Mudan, P P Tekkis.   

Abstract

INTRODUCTION: The traditional surgical management for patients presenting with synchronous colorectal liver metastases (SCLM) has been a delayed resection. However, in some centres, there has been a shift in favour of 'simultaneous' resections. The aim of this study was to use a meta-analytical model to compare the short-term and long-term outcomes in patients with synchronous colorectal liver metastases (SCLM) undergoing simultaneous resections versus delayed resections.
METHOD: Comparative studies published between 1991 and 2010 were included. Evaluated endpoints were intra-operative parameters, post-operative parameters, post-operative adverse events and survival. A random-effects meta-analytical model was used and sensitivity analysis performed to account for bias in patient selection.
RESULTS: Twenty-four non-randomized studies were included, reporting on 3159 patients of which 1381 (43.7%) had simultaneous resections and 1778 (56.3%) had delayed resections. The bilobar distribution (P = 0.01), size of liver metastases (P < 0.001) and the proportion of major liver resections (P < 0.001) was found to be higher in the delayed resection group compared to the simultaneous resection group. There was no significant difference in operative blood loss (95% CI, -279.28, 22.53; P = 0.1) or duration of surgery (WMD -23.83, 95% CI, -85.04, 37.38; P = 0.45). Duration of hospital stay was significantly reduced in simultaneous resections by 5.6 days (95% CI: 2.4-8.9 days, P = 0.007) No significant differences in post-operative complications (36% vs 37%, P = 0.27), overall survival (HR 1.00, 95% CI 0.86-1.15, P = 0.96) or disease free survival (HR 0.85, 95% CI 0.71-1.02, P = 0.08) were found. Sensitivity analysis revealed that these findings were consistent for the duration of hospital stay, post-operative complications, overall survival and disease free survival.
CONCLUSION: This study demonstrates that the selection criteria for patients undergoing simultaneous or delayed resections differs resulting in a discrepancy in the metastatic disease severity being compared between the two groups. The comparable intra-operative parameters, post-operative complications and survival found between the two groups suggest that delayed resections may result in better outcomes. Similarly, the reduced length of hospital stay in simultaneous resections may only be as a result of the reduced disease severity in this group. Simultaneous resections can only be recommended in patients with limited hepatic disease until prospective studies comparing similar disease burdens between the two resection groups are available.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23253399     DOI: 10.1016/j.suronc.2012.11.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  30 in total

1.  A NSQIP Review of Major Morbidity and Mortality of Synchronous Liver Resection for Colorectal Metastasis Stratified by Extent of Liver Resection and Type of Colorectal Resection.

Authors:  Christopher R Shubert; Elizabeth B Habermann; John R Bergquist; Cornelius A Thiels; Kristine M Thomsen; Walter K Kremers; Michael L Kendrick; Robert R Cima; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2015-08-04       Impact factor: 3.452

2.  Synchronous resections of primary colorectal tumor and liver metastasis by laparoscopic approach.

Authors:  Tan To Cheung; Ronnie Tung Ping Poon
Journal:  World J Hepatol       Date:  2013-06-27

3.  Synchronous totally laparoscopic management of colorectal cancer and resectable liver metastases: a single center experience.

Authors:  Stefano Berti; Elisa Francone; Michele Minuto; Pierfrancesco Bonfante; Carlo Sagnelli; Claudio Bianchi; Alessandra Tognoni; Emilio Falco
Journal:  Langenbecks Arch Surg       Date:  2015-02-14       Impact factor: 3.445

4.  Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.

Authors:  C Lim; A Doussot; M Osseis; F Esposito; C Salloum; J Calderaro; C Tournigand; D Azoulay
Journal:  Clin Transl Oncol       Date:  2018-03-28       Impact factor: 3.405

5.  Strategies for Management of Synchronous Colorectal Metastases.

Authors:  Jason A Castellanos; Nipun B Merchant
Journal:  Curr Surg Rep       Date:  2014-06-01

6.  Laparoscopic Approach for Primary Colorectal Cancer Improves Outcome of Patients Undergoing Combined Open Hepatic Resection for Liver Metastases.

Authors:  Francesca Ratti; Marco Catena; Saverio Di Palo; Carlo Staudacher; Luca Aldrighetti
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

7.  Timing of Perioperative Chemotherapy Does Not Influence Long-Term Outcome of Patients Undergoing Combined Laparoscopic Colorectal and Liver Resection in Selected Upfront Resectable Synchronous Liver Metastases.

Authors:  Francesca Ratti; David Fuks; Federica Cipriani; Brice Gayet; Luca Aldrighetti
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

8.  Management of colorectal cancer with synchronous liver metastases: impact of multidisciplinary case conference review.

Authors:  Kerollos N Wanis; Karen Pineda-Solis; Mauro E Tun-Abraham; Jake Yeoman; Stephen Welch; Kelly Vogt; Julie Ann M Van Koughnett; Michael Ott; Roberto Hernandez-Alejandro
Journal:  Hepatobiliary Surg Nutr       Date:  2017-06       Impact factor: 7.293

9.  Impact of totally laparoscopic combined management of colorectal cancer with synchronous hepatic metastases on severity of complications: a propensity-score-based analysis.

Authors:  Francesca Ratti; Marco Catena; Saverio Di Palo; Carlo Staudacher; Luca Aldrighetti
Journal:  Surg Endosc       Date:  2016-03-04       Impact factor: 4.584

Review 10.  Management of colorectal cancer presenting with synchronous liver metastases.

Authors:  Ajith K Siriwardena; James M Mason; Saifee Mullamitha; Helen C Hancock; Santhalingam Jegatheeswaran
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.